Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report issued on Sunday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of Ayala Pharmaceuticals stock opened at $0.11 on Friday. The firm’s fifty day simple moving average is $0.04 and its 200-day simple moving average is $0.16. The stock has a market capitalization of $4.48 million, a price-to-earnings ratio of -0.01 and a beta of 1.81. Ayala Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $1.49.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.